AbbVie Inc (ABBV)vsFortrea Holdings Inc. (FTRE)
ABBV
AbbVie Inc
$290.89
+1.68%
HEALTHCARE · Cap: $504.37B
FTRE
Fortrea Holdings Inc.
$23.14
-10.61%
HEALTHCARE · Cap: $2.14B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2306% more annual revenue ($64.39B vs $2.68B). ABBV leads profitability with a 9.8% profit margin vs -3.2%. FTRE appears more attractively valued with a PEG of 0.34. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
FTRE
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$290.89
$137.92 premium
Margin of Safety
-39.5%
Fair Value
$8.31
Current Price
$23.14
$14.83 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Operating margin of 2.6%
Weak financial health signals
ROE of -85.0% — below average capital efficiency
Revenue declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : FTRE
The strongest argument for FTRE centers on PEG Ratio. PEG of 0.34 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : FTRE
The primary concerns for FTRE are Operating Margin, Piotroski F-Score, Return on Equity. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while FTRE is a turnaround play — different risk/reward profiles.
FTRE carries more volatility with a beta of 1.91 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 41/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Fortrea Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?